title: Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
abstract: Previous studies with gonadotrophin releasing hormone (GnRH/LHRH) vaccines have shown the usefulness of immunization against this hormone in prostate cancer. To this end, we have generated a completely synthetic peptide modified at position 6 and attached to the 830-844 tetanic toxoid (TT) helper T cell sequence. Through this work we have demonstrated that the GnRHm1-TT molecule was highly immunogenic when it is formulated as an oil-based emulsion adjuvated with Montanide ISA 51. That results correlated directly with testosterone reduction and tumor growth inhibition of the Dunning R3327-H androgen responsive prostate tumor model in rats. GnRHm1-TT, proved to be safe and useful for future clinical trials.
authors.affiliation: Department of Cancer, Center for Genetic Engineering and Biotechnology of Camaguey, CP 70100, Apdo 387, Camaguey, Cuba. jesus.junco@cigb.edu.cu
authors.forename: Jesús A
authors.initials: JA
authors.lastname: Junco
authors.forename: Peter
authors.initials: P
authors.lastname: Peschke
authors.forename: Ivan
authors.initials: I
authors.lastname: Zuna
authors.forename: Volker
authors.initials: V
authors.lastname: Ehemann
authors.forename: Franklin
authors.initials: F
authors.lastname: Fuentes
authors.forename: Eddy
authors.initials: E
authors.lastname: Bover
authors.forename: Eulogio
authors.initials: E
authors.lastname: Pimentel
authors.forename: Roberto
authors.initials: R
authors.lastname: Basulto
authors.forename: Osvaldo
authors.initials: O
authors.lastname: Reyes
authors.forename: Lesvia
authors.initials: L
authors.lastname: Calzada
authors.forename: María D
authors.initials: MD
authors.lastname: Castro
authors.forename: Niurka
authors.initials: N
authors.lastname: Arteaga
authors.forename: Yovisleidis
authors.initials: Y
authors.lastname: López
authors.forename: Hilda
authors.initials: H
authors.lastname: Garay
authors.forename: Héctor
authors.initials: H
authors.lastname: Hernández
authors.forename: Ricardo
authors.initials: R
authors.lastname: Bringas
authors.forename: Gerardo E
authors.initials: GE
authors.lastname: Guillén
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000906:Antibodies / Q000097:blood; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000276:immunology; D009829:Oleic Acids / Q000008:administration & dosage / Q000276:immunology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D051381:Rats; D013739:Testosterone / Q000097:blood; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D019496:Cancer Vaccines; D009829:Oleic Acids; D010446:Peptide Fragments; D013745:Tetanus Toxoid; D014614:Vaccines, Synthetic; C477385:montanide ISA 51; D007987:Gonadotropin-Releasing Hormone; D008353:Mannitol; D013739:Testosterone